Background The rapidly expanding clinical adaptation of prostate-specific membrane
antigen (PSMA)-targeted PET imaging in the evaluation of patients with prostate cancer has …

Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that is
highly overexpressed on prostate cancer epithelial cells and for which there is a growing …

Rationale The development of consensus guidelines for interpretation of Prostate-Specific
Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is needed to provide …

Owing to improvements in our understanding of the biological principles of tumour initiation
and progression, a wide variety of novel targeted therapies have been developed …

Background Prostate-specific membrane antigen (PSMA) is the up-and-coming target for
molecular imaging of prostate cancer. Despite its name, non-prostate-related PSMA …

The continuing adoption of prostate specific membrane antigen (PSMA)-targeted PET for
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …

Background To report on imaging findings using 68 Ga-PSMA-HBED-CC PET in a series of
19 breast carcinoma patients. Methods 68 Ga-PSMA-HBED-CC PET imaging results …

68Ga-labelled prostate-specific membrane antigen (PSMA) is emerging as the tool with the
most potential for imaging recurrent prostate cancer [1]. There have been a few reports of …

We present the case of an 87-year-old man with a history of prostatic adenocarcinoma
diagnosed in 2006 and initially treated locally with high intensity focused ultrasound. An …

Because of the broad incidence, morbidity and mortality associated with prostate-derived
cancer, the development of more effective new technologies continues to be an important …